James Smith, MD
Cardiovascular Disease · Saint Louis, MONPI 1902079619
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $913 and has fallen 53.7% since, to $422 in 2025.
Across 121 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$304
- Pfizer$289
- Medtronic$226
- Abiomed$214
- Novartis$199
- Cvrx, Inc.$173
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,60599%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $304 |
| Pfizer | 15 | $289 |
| Medtronic(2 entities) | 5 | $226 |
| Abiomed | 5 | $214 |
| Novartis | 28 | $199 |
| Cvrx, Inc. | 3 | $173 |
| Philips North America LLC | 2 | $162 |
| AstraZeneca | 9 | $143 |
| Boston Scientific | 6 | $139 |
| Siemens Medical Solutions USA, Inc. | 6 | $100 |
| Intuitive Surgical | 1 | $97 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Merck | 4 | $65 |
| Boehringer Ingelheim | 3 | $63 |
| Kestra Medical Technology Services, Inc. | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Amgen | 3 | $51 |
| Scpharmaceuticals Inc. | 2 | $42 |
| Edwards Lifesciences | 1 | $35 |
| Chiesi USA, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $27 |
| Heartflow, Inc. | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,643 in reported general payments places this provider in the 55th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 460 | $492,371 |
| EntrestoSacubitril/Valsartan | 84 | $112,576 |
| FarxigaDapagliflozin Propanediol | 106 | $105,719 |
| XareltoRivaroxaban | 66 | $82,907 |
| Repatha SureclickEvolocumab | 45 | $49,209 |
| JardianceEmpagliflozin | 38 | $39,344 |
| BrilintaTicagrelor | 43 | $31,685 |
| Praluent PenAlirocumab | 29 | $30,707 |
| Ranolazine ErRanolazine | 27 | $5,956 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $4,924 |
| Metoprolol Succinate | 500 | $4,727 |
| ClopidogrelClopidogrel Bisulfate | 369 | $4,265 |
| Atorvastatin Calcium | 351 | $3,904 |
| Amiodarone Hcl | 67 | $3,146 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 49 | $2,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $289 | $492,371460 claims |
| AstraZenecaFarxiga, Brilinta | $143 | $137,404149 claims |
| NovartisEntresto | $199 | $112,57684 claims |
| Johnson & JohnsonXarelto | $27 | $82,90766 claims |
| Boehringer IngelheimJardiance | $63 | $39,34438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.